GLPwatch
Adlyxin for Alzheimer's disease
lixisenatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCAdlyxin (lixisenatide) is not FDA-approved for Alzheimer's disease, and any use for this condition is off-label or investigational. Research in animal models suggests lixisenatide may have neuroprotective effects and improve memory and synaptic function, but these findings have not been confirmed in humans.
AI summary of the sources below.
| Drug | Adlyxin (lixisenatide) |
|---|---|
| Condition | Alzheimer's disease |
| Approval status | Investigational / off-label |
| Research papers | 7 |
Adlyxin is not FDA-approved for alzheimer's disease; the research below reflects investigational or off-label study only.
Research on lixisenatide for alzheimer's disease (7)
- Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.
- Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.
- Lixisenatide rescues spatial memory and synaptic plasticity from amyloid β protein-induced impairments in rats.
- Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease.
- Lixisenatide improves recognition memory and exerts neuroprotective actions in high-fat fed mice.
- Lixisenatide attenuates the detrimental effects of amyloid β protein on spatial working memory and hippocampal neurons in rats.
- Lixisenatide Reduced Damage in Hippocampus CA1 Neurons in a Rat Model of Cerebral Ischemia-Reperfusion Possibly Via the ERK/P38 Signaling Pathway.